ArticleThe Journal of rheumatology2025
Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019).
Article in The Journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recurrent Ischemic Strokes Caused by HSV-2-Associated Cerebral Vasculitis in Antisynthetase Syndrome.The American journal of case reports · 2026Article
- Idiopathic inflammatory myopathies: a comprehensive review, new concepts on diagnostic imaging and whole-body MRI.European radiology · 2026Review
- Fever and rhabdomyolysis in a recent traveler: A case report of an uncommon presentation of anti-synthetase syndrome.SAGE open medical case reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
objectivePopulation-based epidemiology studies about antisynthetase syndrome (ASS) are lacking. Our aims were to determine the incidence and prevalence of ASS and assess malignancy risk among patients following ASS diagnosis.
methodsA retrospective, population-based cohort of adults with incident ASS residing in Olmsted County, Minnesota, in 1998-2019, was assembled. Fulfillment of Solomon classification criteria for ASS and clinical data were collected by manual chart review. Patients were followed until death, migration from the area, or December 31, 2019. Malignancy was defined by physician diagnosis in the medical record. Incidence rate was age- and sex-adjusted to the 2010 US White population. Point prevalence rate was obtained on January 1, 2015.
resultsThirteen patients with ASS were identified (7 [54%] female, 13 [100%] White, median age 44.9 [IQR 41.9-58.3] years). The age- and sex-adjusted incidence of ASS was 0.56 (95% CI 0.25-0.87) per 100,000 population. Incidence was highest in the 50-59 age group. Age- and sex-adjusted prevalence was 9.21 per 100,000 (95% CI 3.44-14.98). Two of 13 (15%) were diagnosed with malignancy within the follow-up interval and none within 3 years of ASS diagnosis. At median 11.9 (IQR 7.0-13.4) years of follow-up, 12/13 (92%) of patients were alive.
conclusionASS is rare, with an incidence of 0.56 per 100,000 population and prevalence of 9.21 per 100,000. In this cohort, incidence was similar between male and female individuals, and was highest in persons aged 50-59 years. None of the patients developed malignancy within 3 years of ASS diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.